IGC Pharma, Inc.
IGC
$0.4601
$0.070117.97%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.59% | 11.86% | 25.98% | 41.58% | -50.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.59% | 11.86% | 25.98% | 41.58% | -50.99% |
| Cost of Revenue | 59.63% | 41.94% | 115.49% | 82.91% | -63.67% |
| Gross Profit | -5.52% | -9.94% | -21.80% | 13.79% | -36.08% |
| SG&A Expenses | -26.70% | -72.27% | -49.28% | -25.48% | 1.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.59% | -44.19% | -33.32% | -21.93% | -1.20% |
| Operating Income | 19.75% | 49.86% | 37.36% | 29.35% | -11.85% |
| Income Before Tax | 32.76% | 58.51% | 67.28% | 29.95% | -14.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.76% | 58.51% | 67.28% | 29.95% | -14.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.76% | 58.51% | 67.28% | 29.95% | -14.60% |
| EBIT | 19.75% | 49.86% | 37.36% | 29.35% | -11.85% |
| EBITDA | 20.24% | 52.47% | 39.36% | 30.78% | -12.42% |
| EPS Basic | 40.98% | 66.59% | 73.09% | 49.89% | 16.37% |
| Normalized Basic EPS | 40.59% | 65.16% | 49.48% | 50.00% | 16.53% |
| EPS Diluted | 40.98% | 66.59% | 73.09% | 49.89% | 16.37% |
| Normalized Diluted EPS | 40.59% | 65.16% | 49.48% | 50.00% | 16.53% |
| Average Basic Shares Outstanding | 14.03% | 23.88% | 21.82% | 39.97% | 37.18% |
| Average Diluted Shares Outstanding | 14.03% | 23.88% | 21.82% | 39.97% | 37.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |